Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05369884Early Phase 1Unknown

Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D

Role: collaborator

NCT02781285Unknown

Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score

Role: collaborator

NCT03658291Phase 4Unknown

Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection

Role: collaborator

NCT02094638Completed

Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Role: collaborator

All 4 trials loaded